Maltol Improves Peripheral Nerve Function by Inhibiting Schwann Cell Apoptosis via the PERK/eIF2α/CHOP Pathway and MME Upregulation in Diabetic Peripheral Neuropathy
-
Published:2024-08-29
Issue:9
Volume:17
Page:1139
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Li Jiawei1, Liu Quan2, Liu Shuainan2ORCID, Xin Hong1, Zhang Xuemei1, Guo Nan1
Affiliation:
1. Minhang Hospital, School of Pharmacy, Fudan University, Shanghai 201203, China 2. Key Laboratory of Polymorphic Drugs of Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract
Diabetic peripheral neuropathy (DPN) is the most prevalent chronic complication among diabetic patients and a primary risk factor contributing to the deterioration of diabetic foot conditions. The pathogenesis of DPN remains complex and not fully understood, and there are hardly any effective treatment drugs. Maltol (3-hydroxy-2-methyl-4-pyranone) has demonstrated antioxidant and anti-inflammatory properties. However, the potential role of maltol in the treatment of DPN remains unclear. This study aimed to assess maltol’s effects on DPN rats and high glucose (HG)/palmitic acid (PA)-induced rat Schwann cells (RSC96). The results indicated maltol’s capacity to enhance peripheral nerve function in DPN rats. In RSC96 cells stimulated with high HG and PA, maltol treatment reduced DPN markers and apoptosis-related proteins. Functional enrichment analysis of differentially expressed genes revealed that endoplasmic reticulum (ER) stress pathways were involved in this process. Western blot results demonstrated the activation of ER stress pathway in HG/PA-induced RSC96 cells, with maltol attenuating ER stress-related protein expression. Furthermore, the knockdown of Membrane metallo-endopeptidase (MME) reversed maltol’s effects on apoptosis-related protein expression, suggesting a potential therapeutic role for maltol via MME in treating DPN. These findings indicate that maltol may hold promise as a therapeutic agent for DPN treatment.
Funder
Shanghai Committee of Science and Technology Natural Science Research Project of Shanghai Minhang District Fundamental Research Fund of Minhang Hospital
Reference39 articles.
1. Yang, K., Wang, Y., Li, Y.-W., Chen, Y.-G., Xing, N., Lin, H.-B., Zhou, P., and Yu, X.-P. (2022). Progress in the treatment of diabetic peripheral neuropathy. Biomed. Pharmacother., 148. 2. Novel drugs affecting diabetic peripheral neuropathy;Saleh;Iran. J. Basic Med. Sci.,2024 3. Painful Diabetic Peripheral Neuropathy: Presentations, Mechanisms, and Exercise Therapy;Yoo;J. Diabetes Metab.,2013 4. Markova, L., Cvetko, E., Ugwoke, C.K., Horvat, S., Umek, N., Stopar, N., and Pintarič, T.S. (2022). The Influence of Diabetic Peripheral Neuropathy on the Duration of Sciatic Nerve Block with 1.3% Liposomal Bupivacaine and 0.25% Bupivacaine Hydrochloride in a Mouse Model. Pharmaceutics, 14. 5. Fibrinogen function indexes are potential biomarkers of diabetic peripheral neuropathy;Zhuang;Diabetol. Metab. Syndr.,2022
|
|